Please use this identifier to cite or link to this item:
https://scidar.kg.ac.rs/handle/123456789/10448
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.rights.license | restrictedAccess | - |
dc.contributor.author | Volarevic, Vladislav | - |
dc.contributor.author | Lukic, Miodrag | - |
dc.date.accessioned | 2021-04-20T15:46:53Z | - |
dc.date.available | 2021-04-20T15:46:53Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 0097-6156 | - |
dc.identifier.uri | https://scidar.kg.ac.rs/handle/123456789/10448 | - |
dc.description.abstract | Despite the fact that all galectins have a galactose-defined specificity, galectin-3 has important pro-inflammatory role while other members of the galectin family, including galectin-1, galectin-2, galectin-4, galectin-9, mainly have anti-inflammatory effects in autoimmune disorders. The basis for such a completely opposite effect of galectin-3 in immune regulation remains unclear and merits further in-depth investigation. It is important that galectin-3 has pro-inflammatory role in T-cell mediated diseases: Con A induced hepatitis, MLD-STZ diabetes, EAE and antigen induced arthritis. Targeting galectin-3 as endogenous inflammatory mediator should serve as a platform for designing novel drugs with aim to prevent or resolve the inflammatory response in T cell mediated autoimmune pathology. © 2012 American Chemical Society. | - |
dc.rights | info:eu-repo/semantics/restrictedAccess | - |
dc.source | ACS Symposium Series | - |
dc.title | Autoimmune disorders in galectin-3 deficient mice | - |
dc.type | conferenceObject | - |
dc.identifier.doi | 10.1021/bk-2012-1115.ch021 | - |
dc.identifier.scopus | 2-s2.0-84905235068 | - |
Appears in Collections: | Faculty of Medical Sciences, Kragujevac |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
PaperMissing.pdf Restricted Access | 29.86 kB | Adobe PDF | View/Open |
Items in SCIDAR are protected by copyright, with all rights reserved, unless otherwise indicated.